spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  eslicarbazepine 

 HSMN NewsFeed - 1 Sep 2016
Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 May 2012
Eisai Gains Positive CHMP Opinion for Fycompa(R) (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 3 Sep 2009
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Feb 2009
Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 24 Sep 2008
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jun 2008
Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Jun 2008
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2008
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2008
Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada
Biopharmaceuticals Neurology Licensing
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.